Clinical study of bevacizumab combined with Huaier granule in the treatment of non-small cell lung cancer

Nian Liang; Wang Jia; Wang Zhishang

doi:10.3760/j.issn.1673-4777.2025.06.018

Abstract：Objective To investigate the effect of bevacizumab combined with Huaier granule in the treat-ment of non-small cell lung cancer.Methods A total of 84 patients with non-small cell lung cancer who were treated in Yan'an University Affiliated Hospital from January 2021 to October 2023 were included in this study.According to the random number table method,they were divided into the control group and the observation group,with 42 cases in each group.On the basis of conventional treatment,the control group was treated with bevacizumab injection,and the observation group was treated with bevacizumab injection combined with Huaier granule.Both groups were treated for 12 weeks.The clinical efficacy,traditional Chinese medicine symptom score,tumor markers,quality of life and adverse reactions were compared between the two groups.Results The disease control rate of the observation group was significantly higher than that of the control group[85.7％(36/42)vs 66.7％(28/42)](P=0.040).After treatment,the scores of chest tightness,cough,dry stool and chest pain in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(all P＜0.05).After treatment,the levels of carbohydrate antigen 125,pro-gastrin-releasing peptide and carcinoembryonic antigen in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(all P＜0.05).After treatment,the scores of physical function,social function,mental psychology and general feeling of the two groups were higher than those before treatment,and those in the observation group were higher than those in the control group(all P＜0.05).There was no significant difference in the incidence of nausea and vomiting,abnormal liver and kidney function,alopecia,skin reaction and toxic myelosuppression between the two groups(all P＞0.05).Conclusion Bevacizumab combined with Huaier granule in the treatment of non-small cell lung cancer has a good therapeutic effect,which can improve the traditional Chinese medicine symptoms,serum tumor markers and quality of life of patients.